Abacus Wealth Partners LLC Makes New $1.53 Million Investment in Gilead Sciences, Inc. $GILD

Abacus Wealth Partners LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,486 shares of the biopharmaceutical company’s stock, valued at approximately $1,533,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter worth about $28,000. Financial Consulate Inc. lifted its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its holdings in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the last quarter. MTM Investment Management LLC lifted its holdings in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $31,000. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. This represents a 18.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares in the company, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 63,000 shares of company stock worth $9,238,250 in the last 90 days. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GILD. Deutsche Bank Aktiengesellschaft upped their target price on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Morgan Stanley reduced their target price on Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. BMO Capital Markets upped their target price on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Cantor Fitzgerald reduced their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Finally, Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.04.

Gilead Sciences Trading Down 1.9%

NASDAQ:GILD opened at $129.58 on Friday. The stock’s 50 day moving average price is $137.76 and its 200 day moving average price is $133.22. Gilead Sciences, Inc. has a 52 week low of $100.23 and a 52 week high of $157.29. The company has a market capitalization of $160.88 billion, a P/E ratio of 17.65 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.